FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1239-1240 May 4, 1995 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Ifosfamide is a chemotherapeutic agent used in the treatment of cervical carcinoma, soft-tissue sarcomas, and germ-cell tumors. Myelosuppression is common. Hemorrhagic cystitis is prevented by the administration of mesna. Confusion and coma have been associated with the use of ifosfamide, and antiepileptic drugs may be required.¹ Ifosfamide may also cause a dose-dependent encephalopathy in the presence of a pelvic mass that obstructs the ureters or intrinsic renal impairment.² The drug is marketed in the United States as Ifex (Bristol-Myers Oncology Division, Princeton, N.J.).

We report the reversal of ifosfamide-associated encephalopathy with methylene blue in a 68-year-old woman . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Patel, P. N (2006). Methylene Blue for Management of Ifosfamide-Induced Encephalopathy. The Annals of Pharmacotherapy 40: 299-303 [Abstract] [Full Text]  
• Bach, K. K., Lindsay, F. W., Berg, L. S., Howard, R. S. (2004). Prolonged Postoperative Disorientation After Methylene Blue Infusion During Parathyroidectomy. Anesth. Analg. 99: 1573-1574 [Abstract] [Full Text]  
• Donegan, S. (2001). Novel treatment for the management of ifosfamide neurotoxicity: Rationale for the use of methylene blue. J Oncol Pharm Pract 6: 153-165 [Abstract]  
• Aeschlimann, C., Küpfer, A., Schefer, H., Cerny, T. (1998). Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. Drug Metab. Dispos. 26: 883-890 [Abstract] [Full Text]